|Videos|July 17, 2017
FDA Approval in ALL, Priority Reviews in CML and Breast Cancer, and More
Advertisement
Gina Columbus reports on an FDA approval in acute lymphoblastic leukemia, priority reviews in chronic myeloid leukemia and breast cancer, ODAC recommendations in ALL and and acute myeloid leukemia, and a clinical hold on 3 multiple myeloma trials.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5
































